Semaglutide
well-studiedA GLP-1 receptor agonist originally developed for type 2 diabetes, now the most prescribed weight loss medication worldwide.
Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the incretin hormone GLP-1. It was developed by Novo Nordisk and is sold under brand names Ozempic (diabetes) and Wegovy (weight management). It works by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and reducing appetite through central nervous system effects.
Clinical trials (STEP program) demonstrated average weight loss of 15-17% of body weight over 68 weeks. It has become one of the most significant pharmaceutical developments in obesity treatment, with global demand consistently outpacing supply.
Benefits
- ✓Significant weight loss (15-17% average)
- ✓Improved glycemic control
- ✓Reduced cardiovascular risk
- ✓Decreased appetite and food cravings
- ✓Potential neuroprotective effects (under investigation)
- ✓Once-weekly dosing
Side Effects
- ⚠Nausea (most common, usually transient)
- ⚠Vomiting and diarrhea
- ⚠Constipation
- ⚠Potential pancreatitis risk
- ⚠Gallbladder issues
- ⚠Muscle loss if not combined with exercise
- ⚠Thyroid C-cell tumor risk (animal studies)
⚠ Research Disclaimer: This information is for educational purposes only and is not medical advice. Consult a qualified healthcare professional before using Semaglutide or any peptide. See our full medical disclaimer.